Association between perfluoroalkyl substances exposures and depression in the adults: Based on NHANES 2005~2018
JU Ying-hui1, WU Rui1, WANG Meng-lin1, GAO Ya2, ZHU Yue1
1. Ion Medical Center of the First Affiliated Hospital of University of Science and Technology of China(Hefei Ion Medical Center), Hefei 230088, China; 2. The Department of Anesthesiology, Anhui Provincial Children's Hospital, Hefei 230051, China
Abstract：To investigate the relationship between perfluoroalkyl substances (PFAS) exposure and the risk of adult depression. We integrated the data in National Health and Nutrition Examination Survey (NHANES) database from 2005 to 2018, and recruited a total of 5424 men and 5438 women. We examined the association between four PFAS exposures, including perfluorooctanoic acid (PFOA), perfluorooctanesulfonate acid (PFOS), perfluorohexanesulfonic acid (PFHxS), perfluorononanoic acid (PFNA), and the risk of adult depression using a weighted logistic regression model and restricted cubic spline curves. Subgroup analysis was also conducted according to gender and age. After adjusting for all covariates, higher exposure to PFOA, PFOS, PFHxS, and PFNA significantly reduced the risk of depression. Compared to the first quartile (Q1), the odds ratios of the groups with the fourth quartile (Q4) level of PFOA, PFOS, PFHxS and PFNA were 0.519 (95%CI: 0.367~0.735), 0.612 (95%CI: 0.422~0.887) and 0.608 (95%CI: 0.422~0.875) and 0.658 (95%CI: 0.467~0.927), respectively. Restricted cubic splines showed a negative linear dose-response relationship between PFAS exposure and the prevalence of depression. Subgroup analysis found that the negative association between PFAS exposure and depression was more significant in women and individuals aged 18~39 years, respectively. Our study suggests a negative association between PFAS exposure and adult depression risk, with gender and age differences. However, more investigations are needed to confirm our findings.
鞠营辉, 吴睿, 王梦琳, 高雅, 朱岳. 全氟烷基化合物暴露与成年人抑郁症间的关系：基于NHANES 2005~2018[J]. 中国环境科学, 2023, 43(9): 4934-4941.
JU Ying-hui, WU Rui, WANG Meng-lin, GAO Ya, ZHU Yue. Association between perfluoroalkyl substances exposures and depression in the adults: Based on NHANES 2005~2018. CHINA ENVIRONMENTAL SCIENCECE, 2023, 43(9): 4934-4941.
Touloumis C. The burden and the challenge of treatment-resistant depression[J]. Psychiatriki, 2021,32(Supplement I):11-14.
[2]
Global burden of 369 diseases and injuries in 204 countries and territories, 1990~2019:a systematic analysis for the Global burden of disease study 2019[J]. Lancet, 2020,396(10258):1204-1222.
[3]
Jacobson M H, Ghassabian A, Gore A C, et al. Exposure to environmental chemicals and perinatal psychopathology[J]. Biochem Pharmacol, 2022,195:114835.
[4]
Dhore R, Murthy G S. Per/polyfluoroalkyl substances production, applications and environmental impacts[J]. Bioresour Technol, 2021, 341:125808.
[5]
Steenland K, Winquist A. PFAS and cancer, a scoping review of the epidemiologic evidence[J]. Environ Res, 2021,194:110690.
[6]
宋博宇,郑哲,吕继涛,等.全氟和多氟烷基类化合物(PFASs)的环境转化与分类管控[J]. 环境科学研究, 2022,35(9):2047-2057. Song Boyu, Zheng Zhe, LU Jitao, et al. Environmental transformation and classified management of per-and polyfluoroalkyl substances (PFASs)[J]. Res. of Environ. Sci., 2022,35(9):2047-2057.
[7]
Ghassabian A, Vandenberg L, Kannan K, et al. Endocrine-disrupting chemicals and child health[J]. Annu. Rev. Pharmacol. Toxicol., 2022, 62:573-594.
[8]
Grønnestad R, Johanson S M, Müller M H B, et al. Effects of an environmentally relevant PFAS mixture on dopamine and steroid hormone levels in exposed mice[J]. Toxicol. Appl. Pharmacol., 2021, 428:115670.
[9]
Yu N, Wei S, Li M, et al. Effects of perfluorooctanoic acid on metabolic profiles in brain and liver of mouse revealed by a high-throughput targeted metabolomics approach[J]. Sci. Rep., 2016, 6:23963.
[10]
张鑫彤.氯胺酮通过多巴胺第二受体对抑郁样大鼠的调节作用[D]. 哈尔滨:东北农业大学, 2020. Zhang Xintong. Regulatory effect of ketamine on depression-like rats through the dopamine D2 receptor[D]. Haerbin:Northeast Agricultural University, 2020.
[11]
Duman R S, Sanacora G, Krystal J H. Altered connectivity in Depression:GABA and glutamate Neurotransmitter deficits and reversal by novel treatments[J]. Neuron, 2019,102(1):75-90.
[12]
Johnson C L, Paulose-Ram R, Ogden C L, et al. National health and nutrition examination survey:analytic guidelines, 1999~2010[J]. Vital Health Stat 2, 2013,(161):1-24.
[13]
Manea L, Gilbody S, Mcmillan D. A diagnostic meta-analysis of the Patient Health Questionnaire-9(PHQ-9) algorithm scoring method as a screen for depression[J]. Gen. Hosp. Psychiatry, 2015,37(1):67-75.
[14]
Kroenke K, Spitzer R L, Williams J B. The PHQ-9:validity of a brief depression severity measure[J]. J. Gen. Intern. Med., 2001,16(9):606-613.
[15]
Kuklenyik Z, Needham L L, Calafat A M. Measurement of 18perfluorinated organic acids and amides in human serum using on-line solid-phase extraction[J]. Anal. Chem., 2005,77(18):6085-6091.
[16]
Buckman J E J, Underwood A, Clarke K, et al. Risk factors for relapse and recurrence of depression in adults and how they operate:A four-phase systematic review and meta-synthesis[J]. Clin. Psychol. Rev., 2018,64:13-38.
[17]
Li X Y, Liu H, Zhang L Y, et al. Association between dietary theobromine with depression:a population-based study[J]. BMC Psychiatry, 2022,22(1):769.
[18]
Fong P, Chan S T, Lei P N, et al. Association of suicidal ideation and depression with the use of proton pump inhibitors in adults:a cross-sectional study[J]. Sci. Rep., 2022,12(1):19539.
[19]
Xiong X, Chen B, Wang Z, et al. Association between perfluoroalkyl substances concentration and bone mineral density in the US adolescents aged 12-19years in NHANES 2005-2010[J]. Front Endocrinol (Lausanne), 2022,13:980608.
[20]
Vuong A M, Yolton K, Braun J M, et al. Polybrominated diphenyl ether (PBDE) and poly-and perfluoroalkyl substance (PFAS) exposures during pregnancy and maternal depression[J]. Environ. Int., 2020,139:105694.
[21]
Aung M T, Eick S M, Padula A M, et al. Maternal per-and poly-fluoroalkyl substances exposures associated with higher depressive symptom scores among immigrant women in the Chemicals in our bodies cohort in San Francisco[J]. Environ. Int., 2023,172:107758.
[22]
Berk M, Williams L J, Andreazza A C, et al. Pop, heavy metal and the blues:secondary analysis of persistent organic pollutants (POP), heavy metals and depressive symptoms in the NHANES National Epidemiological Survey[J]. BMJ Open, 2014,4(7):e005142.
[23]
朱岳,黄东梅,鞠营辉,等.基于网络药理学和分子对接技术探讨黄芪甲苷抗抑郁的作用机制[J]. 现代药物与临床, 2022,37(11):2465-2474. ZHU Yue, HUANG Dongmei, JU Yinghui, et al. Mechanism of astragaloside IV in treatment of depression based on network pharmacology and molecular docking[J]. Drugs & Clin., 2022,37(11):2465-2474.
[24]
Pitsillou E, Bresnehan S M, Kagarakis E A, et al. The cellular and molecular basis of major depressive disorder:towards a unified model for understanding clinical depression[J]. Mol. Biol. Rep., 2020,47(1):753-770.
[25]
Fenton S E, Ducatman A, Boobis A, et al. Per-and polyfluoroalkyl substance toxicity and human health review:Current state of knowledge and strategies for informing future research[J]. Environmental Toxicology and Chemistry, 2021,40(3):606-630.
[26]
Cao Y, Ng C. Absorption, distribution, and toxicity of per-and polyfluoroalkyl substances (PFAS) in the brain:a review[J]. Environ. Sci. Process Impacts, 2021,23(11):1623-1640.
[27]
Li X, Li T, Wang Z, et al. Distribution of perfluorooctane sulfonate in mice and its effect on liver lipidomic[J]. Talanta, 2021,226:122150.
[28]
Starnes H M, Rock K D, Jackson T W, et al. A critical review and meta-analysis of impacts of per-and polyfluorinated substances on the brain and behavior[J]. Front. Toxicol., 2022,4:881584.
[29]
Piekarski D J, Diaz K R, Mcnerney M W. Perfluoroalkyl chemicals in neurological health and disease:Human concerns and animal models[J]. Neurotoxicology, 2020,77:155-168.
[30]
Merrill A K, Conrad K, Marvin E, et al. Effects of gestational low dose perfluorooctanoic acid on maternal and "anxiety-like" behavior in dams[J]. Front Toxicol., 2022,4:971970.
[31]
Hallgren S, Fredriksson A, Viberg H. More signs of neurotoxicity of surfactants and flame retardants-Neonatal PFOS and PBDE 99cause transcriptional alterations in cholinergic genes in the mouse CNS[J]. Environ. Toxicol. Pharmacol., 2015,40(2):409-416.
[32]
Foguth R M, Flynn R W, De Perre C, et al. Developmental exposure to perfluorooctane sulfonate (PFOS) and perfluorooctanoic acid (PFOA) selectively decreases brain dopamine levels in Northern leopard frogs[J]. Toxicol. Appl. Pharmacol., 2019,377:114623.
[33]
Jiang Q, Gao H, Zhang L. Metabolic Effects PFAS[M]//DEWITT J C. Toxicological effects of perfluoroalkyl and polyfluoroalkyl substances. Cham; Springer International Publishing, 2015:177-201.
[34]
Takacs M L, Abbott B D. Activation of mouse and human peroxisome proliferator-activated receptors (alpha, beta/delta, gamma) by perfluorooctanoic acid and perfluorooctane sulfonate[J]. Toxicol. Sci., 2007,95(1):108-117.
[35]
Park S K, Ding N, Han D. Perfluoroalkyl substances and cognitive function in older adults:Should we consider non-monotonic dose-responses and chronic kidney disease?[J]. Environ. Res., 2021,192:110346.
